CLBT trades 19.2% below Wall Street's consensus target of $19.75.
Last 12 months price action with 12-month analyst target path
The base valuation assumes CLBT achieves its forward estimates and maintains a stable P/E multiple of 50.5x. This scenario reflects the blended consensus of 8 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of July 8, 2026, Cellebrite DI Ltd. (CLBT) has a Wall Street consensus price target of $19.75, based on estimates from 8 covering analysts. With the stock currently trading at $16.57, this represents a potential upside of +19.2%. The company has a market capitalization of $4.13B.
Analyst price targets range from a low of $15.00 to a high of $23.00, representing a 41% spread in expectations. The median target of $20.50 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 8 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, CLBT trades at a trailing P/E of 53.5x and forward P/E of 50.5x. Analysts expect EPS to grow +15.0% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $11.27, with bear and bull scenarios of $7.10 and $14.84 respectively. Model confidence stands at 63/100, reflecting moderate uncertainty in projections.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
AXONAxon Enterprise, Inc. | $51.6B | $640.46 | $652.11 | +1.8% | Buy | 83.3x | 21 |
VRNSVaronis Systems, Inc. | $5.4B | $45.84 | $36.92 | -19.5% | Buy | 385.5x | 34 |
OSPNOneSpan Inc. | $555M | $14.82 | $15.50 | +4.6% | Buy | 12.2x | 15 |
NTCTNetScout Systems, Inc. | $3.0B | $42.37 | $38.00 | -10.3% | Hold | 17.6x | 21 |
IIIVi3 Verticals, Inc. | $473M | $21.40 | $28.00 | +30.8% | Buy | 18.8x | 15 |
SPSCSPS Commerce, Inc. | $2.3B | $60.93 | $67.00 | +10.0% | Hold | 12.9x | 23 |
CACICACI International Inc | $11.0B | $497.36 | $682.40 | +37.2% | Buy | 17.6x | 29 |
SAICScience Applications International Corporation | $4.8B | $113.67 | $111.75 | -1.7% | Hold | 11.3x | 18 |
LDOSLeidos Holdings, Inc. | $13.7B | $108.57 | $174.14 | +60.4% | Buy | 9.2x | 27 |
BAHBooz Allen Hamilton Holding Corporation | $7.6B | $63.31 | $89.50 | +41.4% | Buy | 10.4x | 21 |
Quick answers to the most common questions about buying CLBT stock.
Cellebrite DI Ltd. (CLBT) has a consensus 12-month price target of $19.75, implying 19.2% upside from $16.57. The 8 analysts covering CLBT see moderate appreciation potential.
CLBT has a consensus rating of "Buy" based on 8 Wall Street analysts. The rating breakdown is predominantly bullish, with 8 Buy/Strong Buy ratings. The consensus 12-month price target of $19.75 implies 19.2% upside from current levels.
At a forward P/E of 50.5183x, CLBT trades at a premium valuation. The consensus price target of $19.75 (19.2% upside) suggests analysts still see growth justifying the multiple.
The most bullish Wall Street analyst has a price target of $23 for CLBT, while the most conservative target is $15. The consensus of $19.75 represents the median expectation. Our quantitative valuation model projects a bull case target of $15 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
CLBT is moderately covered, with 8 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 8 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month CLBT stock forecast based on 8 Wall Street analysts shows a consensus price target of $19.75, with estimates ranging from $15 (bear case) to $23 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $11, with bear/bull scenarios of $7/$15.
Our quantitative valuation model calculates CLBT's fair value at $11 (base case), with a bear case of $7 and bull case of $15. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 63/100.
CLBT trades at a forward P/E ratio of 50.5x based on next-twelve-months earnings estimates compared to a trailing P/E of 53.5x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are optimistic on CLBT, with a "Buy" consensus rating and $19.75 price target (19.2% upside). 8 of 8 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
CLBT analyst price targets range from $15 to $23, a 41% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $19.75 consensus represents the middle ground. Our model's $7-$15 range provides an independent fundamental perspective.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.